- not yet recruitingNA
Imaging Based Uveitis Screening for Children With Juvenile Idiopathic Arthritis
This study is looking at how best to check for an eye condition called uveitis in children with juvenile idiopathic arthritis (JIA). It compares standard eye exams with a newer imaging scan (OCT) to see which works better for early detection and to help plan a larger study.
United Kingdom - recruitingPHASE3
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
This study looks at a medicine called baricitinib for children aged 1 to 17 with Juvenile Idiopathic Arthritis (JIA). It checks if the medicine is safe and helps treat their JIA. Participants have been in previous baricitinib studies for JIA.
Argentina · Australia · Austria - authorisedTherapeutic confirmatory (Phase III)
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA)
This study looks at different medicines for children and young people with JIA whose current treatment hasn't worked well enough. We want to find out which medicine best helps control their arthritis and reduces symptoms like pain and tiredness after 6 months.
Italy · Netherlands · Germany - recruitingPHASE2
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
This study is looking at a new medicine called sarilumab for children and teenagers with a type of arthritis called systemic Juvenile Idiopathic Arthritis (sJIA). It aims to find the right dose and see how safe and effective it is.
Argentina · Canada · Finland - recruitingPHASE1
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
This study looks at how a medicine called filgotinib works in the bodies of children and teenagers with a type of arthritis called Juvenile Idiopathic Arthritis (JIA). We want to understand how much medicine is needed and if it's safe for them.
France · Germany · Poland - ongoing, recruitingTherapeutic use (Phase IV)
Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intraarticular glucocorticoid injections in JIA patients starting tumour necrosis factor inhibitor treatment. The MyJIA trial.
This study, called MyJIA, looks at how well a steroid injection into joints works for children with juvenile idiopathic arthritis (JIA) who are also starting a new medicine called a TNF inhibitor. It wants to see if this combined approach helps them stay well for longer.
Norway - active not recruiting
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
This study looks at the long-term safety of a medicine called Abatacept for children and teenagers with a type of arthritis called Juvenile Idiopathic Arthritis (JIA). Researchers want to see how safe it is over time, especially regarding serious infections, other immune problems, and cancer.
United States · Austria · Brazil - recruitingNA
Feasibility of a Diet Intervention for Juvenile Arthritis
This study looks at how a special diet, similar to the Mediterranean diet, affects children with arthritis. We want to see if changing what they eat can help their arthritis and if it changes the good bacteria in their gut.
Canada - not yet recruitingNA
Sarcopenia and Juvenile Idiopathic Arthritis
This study looks at muscle weakness and loss (sarcopenia) in young people and adults with Juvenile Idiopathic Arthritis (JIA) in France. It aims to understand how common it is and what causes it, using questionnaires, strength tests, and body scans to help doctors better support patients in the future.
France - recruitingPHASE3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
This study looks at new treatments for a severe type of childhood arthritis called Systemic Juvenile Idiopathic Arthritis (sJIA). It compares upadacitinib with an existing treatment, tocilizumab, to see how well they work and if they cause any side effects in children aged 1 to 17.
United States · Argentina · Australia